3370 results for «2024»

Filter By

3370 results

Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial

09 Apr 2024

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)

Daniele Giacoppo

Author

Daniele Giacoppo
Marco Spagnolo

Author

Marco Spagnolo
IVUS-guided vs angiography-guided PCI in acute coronary syndromes

NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

02 Sep 2025

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Daniele Giacoppo

Author

Daniele Giacoppo
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial

07 Apr 2024

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Nicola Ryan

Author

Nicola Ryan

Author

Ali Nazmi Calik
REDUCE-AMI: Long-term beta-blocker treatment after AMI and preserved LVEF

Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)

08 Apr 2024

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Author

Ali Nazmi Calik
Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques

BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.

04 Mar 2024

Surgical left atrial appendage occlusion in VHD without AF: OPINION Trial

03 Sep 2025

Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Alessandro Sticchi

Author

Alessandro Sticchi
OPINION Trial: 1-year outcomes

Comparison of drug-coated versus conventional balloons for treatment of side branches of bifurcation lesions: the OCVC-BIF study

29 Oct 2025

Ali Nazmi Calik provides his take on the OCVC-BIF study presented by Takayuki Ishihara at TCT 2025, in San Francisco.

Author

Ali Nazmi Calik
Comparison of drug-coated versus conventional balloons for treatment of side branches of bifurcation lesions: The OCVC-BIF study

lmaging: The eyes of the Heart Team

14 May 2024

More than ever, Heart Team members rely on advanced imaging to guide procedures and aid in decision-making about patient selection and management. Just as imaging plays a prominent role in the cathlab, so it will be central to this year's EuroPCR content, with a track of specially...

lmaging: The eyes of the Heart Team

Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease: the FLAVOUR II trial

29 Mar 2025

Ali Nazmi Calik provides his take on the FLAVOUR II trial presented by Jian-An Wang at ACC.25 in Chicago.

Author

Ali Nazmi Calik
Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease: the FLAVOUR II trial

The effectiveness and safety of a planned investment procedure in high-risk chronic total occlusions - The INVEST CTO single arm study

03 Nov 2025

Kalaivani Mahadevan and Sofia Papadopoulou provide their take on the INVEST CTO trial, presented by Anja Oksnes at TCT 2025, in San Francisco.

Kalaivani Mahadevan

Author

Kalaivani Mahadevan
Sofia Papadopoulou

Author

Sofia Papadopoulou
INVEST-CTO: Single arm study of a planned investment procedure in high-risk CTO PCI
Didn’t find what you were looking for?